Clinical Trial Update: A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating trastuzumab deruxtecan (T-DXd) as monotherapy or in combination with anti-cancer agents for selected HER2-expressing tumors; c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) | Phase 2 | Status: RECRUITING